Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort

被引：0
|
作者：
Kallweit, U. [1 ]
Jelcic, I. [1 ]
Braun, N. [1 ]
Fischer, H. [1 ]
Zoerner, B. [1 ]
Schreiner, B. [1 ]
Sokolov, A. [1 ]
Martin, R. [1 ]
Weller, M. [1 ]
Linnebank, M. [1 ]
机构：
[1] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P950
引用
收藏
页码：S429 / S429
页数：1
相关论文
共 50 条
  • [1] Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort
    Kallweit, Ulf
    Jelcic, Ilijas
    Braun, Nathalie
    Fischer, Heike
    Zoerner, Bjoern
    Schreiner, Bettina
    Sokolov, Arseny A.
    Martin, Roland
    Weller, Michael
    Linnebank, Michael
    CLINICAL NEUROPHARMACOLOGY, 2012, 35 (02) : 77 - 80
  • [2] REAL-LIFE EFFECTIVENESS OF NATALIZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): A REGISTRY ANALYSIS
    Danko, D.
    Manca, A.
    Mor, Z.
    Csepany, T.
    VALUE IN HEALTH, 2014, 17 (03) : A56 - A57
  • [3] Real-life long-term effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort
    Zecca, C.
    Roth, S.
    Findling, O.
    Perriard, G.
    Bachmann, V.
    Pless, M. L.
    Baumann, A.
    Kamm, C. P.
    Lalive, P. H.
    Czaplinski, A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 640 - 640
  • [4] Real-life long-term effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort
    Zecca, C.
    Roth, S.
    Findling, O.
    Perriard, G.
    Bachmann, V.
    Pless, M. L.
    Baumann, A.
    Kamm, C. P.
    Lalive, P. H.
    Czaplinski, A.
    SWISS MEDICAL WEEKLY, 2016, 146 : 80S - 80S
  • [5] Real-life long-term effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort
    Zecca, Chiara
    Roth, Serge
    Findling, Oliver
    Perriard, Guillaume
    Bachmann, Valerie
    Pless, Misha L.
    Baumann, Andreas
    Kamm, Christian P.
    Lalive, Patrice H.
    Czaplinski, Adam
    NEUROLOGY, 2017, 88
  • [6] Efficacy and safety of Natalizumab treatment for relapsing-remitting multiple sclerosis: results from a retrospective French cohort
    Beyrouti, R.
    Courtois, S.
    Penombre, E.
    Mostoufizadeh, S.
    Cohen, E.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 649 - 649
  • [7] REGIONAL EFFICACY OF NATALIZUMAB TREATMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
    Doshi, Anisha
    Voysey, Zanna
    Bunting, Eva
    Malik, Muzaffar
    Rashid, Waqar
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11):
  • [8] Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis is independent of baseline status
    Coles, A. J.
    JOURNAL OF NEUROLOGY, 2007, 254 : 55 - 55
  • [9] Effect of natalizumab on disease activity in relapsing-remitting multiple sclerosis patients
    Agiela, Mabroka I. M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
  • [10] Managing breakthrough disease activity during treatment with natalizumab in relapsing-remitting multiple sclerosis
    Lizak, Nathaniel
    Sharmin, Sifat
    Horakova, Dana
    Havrdova, Eva
    Ayuso, Guillermo Izquierdo
    Madueno, Sara Eichau
    van der Walt, Anneke
    Butzkueven, Helmut
    Lechner-Scott, Jeannette
    Buzzard, Katherine
    Skibina, Olga
    Gerlach, O.
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Alroughani, Raed
    Patti, Francesco
    Grand'Maison, Francois
    Sa, Maria Jose
    Morales, Eduardo Aguera
    Hodgkinson, Suzanne
    Grammond, Pierre
    Kuhle, Jens
    Yamout, Bassem I.
    Khoury, Samia
    Ozakbas, Serkan
    Slee, Mark
    Csepany, Tunde
    John, Nevin A.
    Laureys, Guy
    Van Hijfte, Liesbeth
    Terzi, Murat
    Amato, Maria Pia
    Boz, Cavit
    Al-Asmi, Abdullah
    Cartechini, Elisabetta
    Gouider, Riadh
    Mrabet, Saloua
    Roos, Izanne
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 370 - 372
12345